Equillium, Inc. announced that effective February 4, 2021, the board increased the number of directors to eight and appointed Dr. Yu (Katherine) Xu, Ph.D., as a class II director of the company, effective immediately. Dr. Xu was appointed by Decheng Capital Global Life Sciences Fund IV, L.P. pursuant to the terms of the Purchase Agreement. Dr. Xu does not have any family relationship with any director, executive officer or person nominated or chosen by us to become a director or executive officer. until the annual meeting of shareholders at which Class II directors are appointed and until her successor shall have been elected and qualified or until her earlier death, resignation or removal.